Related Experiment Video
Updated: Jul 19, 2026
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
Published on: September 13, 2014
[Combined non-biological artificial liver in treatment of late stage chronic severe hepatitis]
Jie Jin1, Wei-jiang Ye, Jin-song Huang
1Hangzhou Sixth Peopleos Hospital, Hangzhou 310014, China. jinjie0429@163.com
Objective:
To explore the clinical effects of combined non-biological artificial liver in the treatment of late stage chronic severe hepatitis and especially to observe their effects on hepatic encephalopathy, hepatorenal syndrome and disturbance of electrolytes.
Methods:
103 chronic severe hepatitis patients were treated with the same medical measures, including plasma exchange. Among them, 63 patients were also treated with combinations of non-biological artificial liver (treatment group), and the other 40 patients served as controls (control group). The efficacy of the treatments and survival rates of the two groups were compared.
Results:
In the treatment group, the rate of regaining normal consciousness was 72.7%, the rate of electrolyte disorder being rectified was 89.5%, the rate of restoring renal function was 66.7% and the total survival rate was 47.6%. In comparison, in the control group the rate of regaining normal consciousness was 16.7%, the rate of electrolyte disorder being rectified was 42.3%, none of their renal functions were restored and the total survival rate was 22.5%. The differences between the two groups were significant (chi2=6.56, P less than 0.05).
Conclusion:
With other medical treatment, combined non-biological artificial liver can improve the survival rate of severe hepatitis patients.
